
Sign up to save your podcasts
Or


Co-Founder and CEO Aaron Edwards describes the rational behind this approach, as opposed charging the cells with cytokines or removing their brakes. He also explains why KiraGen is looking abroad to do its first clinical trials.
By BiotechTV5
44 ratings
Co-Founder and CEO Aaron Edwards describes the rational behind this approach, as opposed charging the cells with cytokines or removing their brakes. He also explains why KiraGen is looking abroad to do its first clinical trials.

30,626 Listeners

1,863 Listeners

1,085 Listeners

325 Listeners

6,059 Listeners

60 Listeners

9,840 Listeners

86 Listeners

34 Listeners

19 Listeners

260 Listeners

497 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners